Volociximab

DB06647InvestigationalProtein Based Therapies

Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.

Mechanism: Pharmacologically active on Integrin alpha-5 and Fibronectin receptor
Curator reviewed
Primary indication: Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.Curator reviewed
Code names: EOS-200-4 · M-200

Resolves to

Compound

Targets

What you can answer from here — as of July 03, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

429Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Volociximab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.